KRAS and BRAF: drug targets and predictive biomarkers (Q37815135)

23 August 2017

1 reference

title

KRAS and BRAF: drug targets and predictive biomarkers (English)

1 reference

23 August 2017

0 references

Efsevia Vakiani

1

1 reference

PubMed ID

21125676

23 August 2017

David B Solit

series ordinal

2

1 reference

23 August 2017

28 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

223

1 reference

23 August 2017

2

1 reference

23 August 2017

219-229

1 reference

Proteins regulating Ras and its relatives

23 August 2017

1 reference

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

21 January 2018

1 reference

T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes

21 January 2018

1 reference

Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus

21 January 2018

1 reference

Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses

21 January 2018

1 reference

Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses

21 January 2018

1 reference

Three human transforming genes are related to the viral ras oncogenes

21 January 2018

1 reference

Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line

21 January 2018

1 reference

Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

Regulation and role of Raf-1/B-Raf heterodimerization

21 January 2018

1 reference

MEK kinase activity is not necessary for Raf-1 function

21 January 2018

1 reference

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

21 January 2018

1 reference

Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation

21 January 2018

1 reference

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

Positive and negative regulation of Raf kinase activity and function by phosphorylation

21 January 2018

1 reference

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

21 January 2018

1 reference

Ral GTPases and cancer: linchpin support of the tumorigenic platform

21 January 2018

1 reference

Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

21 January 2018

1 reference

Distinct requirements for Ras oncogenesis in human versus mouse cells

21 January 2018

1 reference

Recurrent KRAS codon 146 mutations in human colorectal cancer

21 January 2018

1 reference

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

21 January 2018

1 reference

21 January 2018

1 reference

The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants

21 January 2018

1 reference

Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins

21 January 2018

1 reference

Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins

21 January 2018

1 reference

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

21 January 2018

1 reference

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

21 January 2018

1 reference

Oncogenic Braf induces melanocyte senescence and melanoma in mice

21 January 2018

1 reference

p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors

21 January 2018

1 reference

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

21 January 2018

1 reference

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

21 January 2018

1 reference

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations

21 January 2018

1 reference

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

21 January 2018

1 reference

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

Pathologic features and biologic importance of colorectal serrated polyps

21 January 2018

1 reference

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 January 2018

1 reference

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

Sorafenib in renal cell carcinoma

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition

21 January 2018

1 reference

Genetic predictors of MEK dependence in non-small cell lung cancer

21 January 2018

1 reference

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

Clinical experience of MEK inhibitors in cancer therapy

21 January 2018

1 reference

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

21 January 2018

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

21 January 2018

1 reference

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

21 January 2018

1 reference

A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting

21 January 2018

1 reference

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

21 January 2018

1 reference

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

21 January 2018

1 reference

Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.

21 January 2018

1 reference

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

21 January 2018

1 reference

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.2796

1 reference

release_nnkig5dheza77j3vgmzztqnzue

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nnkig5dheza77j3vgmzztqnzue

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21125676

1 reference

PubMed ID

21125676